AnaptysBio to abandon eczema drug development

AnaptysBio Stock Under Pressure After Scrapping Eczema Drug Program: Retail Is Devastated
Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking the stock’s steepest single-day loss since March 2021. The collapse followed the company’s announcement that it would halt further investment in its experimental therapy ANB032 after the drug failed to meet primary and
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals
Shares of AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company, plunged 32.8% on Dec. 11 after it announced that the phase IIb study of pipeline candidate, ANB032, a BTLA agonist, was unsuccessful.
AnaptysBio to abandon eczema drug development after mid-stage trial failure
AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 40% lower.
AnaptysBio drops development of ANB032 following trial miss
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema.
AnaptysBio to Drop Eczema Drug Candidate After Trials Miss Endpoints; Shares Fall
The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, often referred to as eczema.
FierceBiotech1d
AnaptysBio scraps atopic dermatitis asset after antibody fails to meet all endpoints in ph. 2
AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data
AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...
Buy Rating on AnaptysBio: Strategic Focus on Rosnilimab Amidst Stock Valuation Opportunity
Derek Archila, an analyst from Wells Fargo, assigned the Buy rating on AnaptysBio (ANAB – Research Report). The associated price target is ...
clinicaltrialsarena6h
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints
AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.
Key Takeaways From AnaptysBio Analyst Ratings
Return on Equity (ROE): AnaptysBio's ROE is below industry averages, indicating potential challenges in efficiently utilizing ...
AnaptysBio downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar downgraded AnaptysBio (ANAB) to Neutral from Buy with a $19 price target Pick the best stocks and maximize ...
Seeking Alpha20d
AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching
AnaptysBio has been able to use its technology to develop 2 compelling lead drug candidates. Their pipeline has 2 key readouts in December 2024 and February 2025 worth monitoring. The near-term ...